Influence of probiotics in the eradication treatment of Helicobacter pylori
Keywords:
probiotics, prebiotics, gut microbiota, Helicobacter pyloriAbstract
Introduction: Scientist Elie Metchnikoff proposed that the consumption of lactic acid bacteria in milk could reduce adverse effects and reduce harmful processes in the body. These observations laid the foundation for the introduction into medical practice of specific microbial strains for the treatment of a wide spectrum of diseases, including the eradication of the Helicobacter pylori bacteria.
Objective: Update the usefulness of probiotics in the eradication treatment of Helicobacter pylori, as well as its relationship with the intestinal microbiota.
Methods: Articles in Spanish and English published in the Scielo, Medline and Cochrane databases were consulted. The terms used for the search were Helicobacter pylori, prebiotics, probiotics and synbiotics.
Development: Currently there is no 100% effective treatment for the eradication of Helicobacter pylori, related to microbial resistance and the adverse effects produced by conventional treatments. In recent years, the usefulness of probiotics and prebiotics in combination with antibiotic therapy has been evaluated to achieve better cure rates. Studies suggest that various strains of probiotics or synbiotics are effective in reducing the occurrence and intensity of adverse effects induced by antibiotics, increasing adherence to treatment, and improving eradication rates.
Conclusions: Some probiotics added to antibiotics may be useful as adjuvant therapy for the eradication of Helicobacter pylori infection by increasing adherence to treatment and improving eradication rates.
References
Guarner F, Sanders ME, Szajewska H, Cohen H, Eliakim R, Herrera C, et al. Probióticos y prebióticos. Guías Mundiales WGO. 2023 [acceso:15/6/2024]:1-55. Disponible en: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-spanish-2023.pdf
Podolsky S. Cultural divergence: Elie Metchnikoff’s Bacillus bulgaricus therapy and his underlying conception of health. Bull Hist Med. 1998 [acceso:15/6/2024];72:1-27. Disponible en: https://www.jstor.org/stable/44451482
Bodke H, Jogdand S. Role of probiotics in Human Health. Cureus. 2022 [acceso:18/6/2024];14(11):e31313. Disponible en: https://doi:10.7759/cureus.31313
Fiorani M, Tohumcu E, Del Vecchio LE, Porcari S, Cammarota G, Gasbarrini A, et al. The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota. Antibiotics. 2023 [acceso:18/6/2024];12(4):765. Disponible en: https://doi.org/10.3390/antibiotics12040765
Ali A, Al Hussaini KI. Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms. 2024 [acceso:18/6/2024];12(1):222. Disponible en: https://doi.org/10.3390/microorganisms12010222
Sun Q, Yuan C, Zhou S, Lu J, Zeng M, Cai X, et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front. Cell. Infect. Microbiol. 2023 [acceso:16/6/2024];13:1257817. Disponible en: https://doi.org/10.3389/fcimb.2023.1257817
Salazar B, Gómez-Villegas SI, Vélez DE, Ramírez V, Pérez T, Martínez A. Frecuencia de la infección por Helicobacter pylori en pacientes que requirieron endoscopia digestiva en siete unidades de tres subregiones de Antioquia. Rev. colomb. Gastroenterol. 2023 [acceso:18/6/2024];38(3):290-303. Disponible en: https://doi.org/10.22516/25007440.983
Huang H, Zhong W, Wang X, Yang Y, Wu T, Chen R, et al. The role of gastric microecological dysbiosis in gastric carcinogenesis. Front. Microbiol. 2023 [acceso:18/6/2024];14:1218395. Disponible en: https://doi.org/10.3389/fmicb.2023.1218395
Ng HY, Leung WK, Cheung KS. Antibiotic Resistance, Susceptibility testing and Stewardship in Helicobacter pylori Infection. Int. J. Mol. Sci. 2023 [acceso:18/6/2024];24(14):11708. Disponible en: https://doi.org/10.3390/ijms241411708
Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch. Microbiol. 2022 [acceso:18/6/2024];204:692. Disponible en: https://doi.org/10.1007/s00203-022-03314-w
Das TK, Pradhan S, Chakrabarti S, Mondal K. Current status of probiotic and related health benefits. Appl. Food Res. 2022 [acceso:18/6/2024];2:100185. Disponible en: https://doi.org/10.1016/j.afres.2022.100185
Rappaccioli R, Zaror V, Herrera S. Probióticos: desafíos, revisión y alcance. Rev. Med Sinergia. 2021 [acceso:18/6/2024];6(6):e686. Disponible en: https://doi.org/10.31434/rms.v6i6.686
Pacheco CK, Saucedo C, Rodríguez LV, Perez L. Características de microorganismos utilizados como probióticos tradicionales y nuevos probióticos. Actual. Biol. 2023 [acceso:14/7/2024];45(119):1-12. Disponible en: https://doi.org/10.17533/udea.acbi/v45n119a05
Hang L, Dan Z, Ren G, Si H, Cai Z, Ao Sh, et al. Effects and Mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narretive review. Nutrients. 2021 [acceso:14/7/2024];13(9):3211. Disponible en: https://doi.org/10.3390/nu13093211
Di Primo AN, Duca G, Rubio C. Actividad de los fructooligosacáridos como prebiótico y efectos sobre el tracto intestinal. Rev Biotecnol. 2021 [acceso:14/7/2024];25(1):10-20. Disponible en: http://hdl.handle.net/11336/185684
Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K et al. The international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 2020 [acceso:12/6/2024];17:687-701. Disponible en: https://doi.org/10.1038/s41575-020-0344-2
Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhito T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit–risk approach? World J Gastroenterol. 2022 [acceso:14/7/2024];28(7):766-774. Disponible en: https://doi.org/10.3748/wjg.v28.i7.766
Huang H, Zhong W, Wang X, Yang Y, Wu T, Chen R, et al. The role of gastric microecological dysbiosis in gastric carcinogenesis. Front. Microbiol. 2023 [acceso:14/7/2024];14:1218395. Disponible en: https://doi.org/10.3389/fmicb.2023.1218395
Fakharian F, Asgari B, Nabavi-Rad A, Sadegh A, Soleimani N, Yadegar A, et al. The interplay between Helicobacter pylori and the gut microbiota: An emerging driver influencing the immune system homeostasis and gastric carcinogenesis. Front. Cell Infect. Microbiol. 2022 [acceso:14/7/2024];12:953718. Disponible en: https://doi.org/10.3389/fcimb.2022.953718
Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021 [acceso:14/7/2024];13(1):1-22. Disponible en: https://doi.org/10.1080/19490976.2021.1909459
Guo Y, Cao XS, Guo GY, Zhou MG, Yu B. Effect of Helicobacter pylori eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis. Front Cell Infect Microbiol. 2022 [acceso:24/8/2024];12:899248. Disponible en: https://doi.org/10.3389/fcimb.2022.899248
Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020 [acceso:14/8/2024];69(9):1598-1607. Disponible en: https://doi.org/10.1136/gutjnl-2019-319696
Saxena A, Mukhopadhyay AK, Nandi SP. Helicobacter pylori: Perturbation and restoration of gut microbiome. J Biosci. 2020 [acceso:14/8/2024];45(1):110. Disponible en: https://doi.org/10.1007/s12038-020-00078-7
Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020 [acceso:14/8/2024];113(12):2019-40. Disponible en: https://doi.org/10.1007/s10482-020-01474-7(0123456789
Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol. 2020 [acceso:24/8/2024];104(23):9891-9905. Disponible en: https://doi.org/10.1007/s00253-020-10945-w
Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, et al. V Conferencia Española de Consenso sobre el tratamiento de la erradicación por Helicobacter pylori. Rev. Gastroenterol Hepatol. 2022 [acceso:24/7/2024];45(5):392-417. Disponible en: https://doi.org/10.1016/j.gastrohep.2021.07.011
Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023 [acceso:24/7/2024];11(20):4740-51. Disponible en: https://dx.doi.org/10.12998/wjcc.v11.i20.4740
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 [acceso:24/7/2024]:327745. Disponible en: https://doi.org/10.1136/gutjnl-2022-327745
Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Leo AD. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol. 2018 [acceso:24/7/2024];24(1):139-49. DOI: 10.3748/wjg.v24.i1.139 Disponible en: https://www.wjgnet.com/1007-9327/full/v24/i1/139.htm
Mestre A, Sathiya Narayanan RS, Rivas D, John J, Abdulgader MA, Khanna T, et al. Role of probiotic in the management of Helicobacter pylori. Cureus. 2022 [acceso:23/7/2024];14(6):e26463. Disponible en: https://doi.org/10.7759/cureus.26463
Wu T, Dong XY, Zhou XZ, Li ZS, Du YQ. Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication. J Dig Dis. 2022 [acceso:23/7/2024];23(8-9):462-72. Disponible en: https://doi.org/10.1111/1751-2980.13138
Nelwan EJ, Herdiman A, Kalaij AGI, Laudita RK, Yusuf SM, Suarthana E. Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis. BMC Infect Dis. 2024 [acceso:23/7/2024];24:505. Disponible en: https://doi.org/10.1186/s12879-024-09259-3
Cifuentes SG, Prado MB, Fornasini M, Cohen H, Baldeón ME, Cárdenas PA. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022 [acceso:23/7/2024];27(2):e12870. Disponible en: https://doi:10.1111/hel.12870
Zhang M, Zhang C, Zhao J, Zhang H, Zhai Q, Chen W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog. 2020 [acceso:23/7/2024];147:104403. Disponible en: https://doi:10.1016/j.micpath.2020.104403
Hamzavi Y, Bashiri H. The effect of quadruple therapy plus probiotics on Helicobacter pylori eradication and antibiotic-associated side effects: A randomized placebo-controlled trial. J Kermanshah Univ Med Sci. 2023 [acceso:23/7/2024];27(4):e137908. Disponible en: https://doi.org/10.5812/jkums-137908
Taco KR, García P. Optimizacion de parámetros para la elaboración de leche acida con Lactobacillus acidophilus. Inf. Tecnol. 2021 [acceso:23/7/2024];32(1):179-186. Disponible en: https://dx.doi.org/10.4067/S0718-07642021000100179
Fontecha J, Juárez M, Calvo MV. Beneficios de las leches fermentadas en la salud. Digital. CSIC. 2022 [acceso:1/8/2024]. Disponible en: https://hdl.handle.net/10261/285279
Rodríguez O, Cortada A, Rodríguez JA, Santos B. Fructooligosacáridos y probióticos en leches fermentadas, una alternativa nutricional y saludable. Ciencia Tecnol Alim. 2023 [acceso:1/8/2024];22(3):53-9. Disponible en: https://revcitecal.iiia.edu.cu/revista/index.php/RCTA/article/view/563
Sachdeva A, Rawat S, NagpalJ. Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: A review. World J Gastroenterol. 2014 [acceso:1/8/2024];20(3):724-37. Disponible en: https://doi.org/10.3748/wjg.v20.i3.724
Mustelier D, Álvares IS, Nápoles O, Crespo LM. Potencialidades para la producción de leche fermentada simbiótica de cabra en Camagüey. Rev Científica YACHASUN. 2021 [acceso:1/8/2024];5(9):122-137. Disponible en: https://doi.org/10.46296/yc.v5i9ucedespcoct.0127
Gil I, Barroso L, Rodríguez O, Chao L, Samada M, Tusen Y, y col. Leche fermentada simbiótica y triple terapia en el tratamiento de Helicobacter pylori. Rev Cub Med Mil. 2022 [acceso:1/8/2024];51(1):e02201662. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article/view/1662/1233
Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol. 2022 [acceso:1/8/2024];12:1042070. Disponible en: https://doi.org/10.3389/fcimb.2022.1042070
Parth K, Prudhivi R, Palatheeya S, Abbas SK, Varsha K, Niharika BV et al. Efficacy of Lactobacillus reuteri suplementation in eradication of H. pylori: A comparison study with triple drug therapy. J Pharm Res Int. 2021 [acceso:1/8/2024];33(52B):151-59. https://doi.org/10.9734/JPRI/2021/v33i52B33611
Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC gastroenterology. 2022 [acceso:1/8/2024];22(1):107. Disponible en: https://doi.org/10.1186/s12876-022-02187-z
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ileana Gil LLanes
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
